A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. Fellow Japanese drugmaker Ono Pharmaceutical has won an FDA green light for vimseltinib to treat ...

Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...

The biotech is hoping to provide an alternative to Daiichi Sankyo’s Turalio (pexidartinib), an oral CSF-1, KIT, and FLT3 inhibitor, which was given the green light by the FDA in 2019 ...

It will compete with Daiichi Sankyo’s CSF1R inhibitor pexidartinib (Turalio), which secured FDA approval in TGCT in 2019. TGCT are rare, non-malignant tumours that form in and near joints.

If it makes it to market, the drug will compete with Daiichi Sankyo's Turalio (pexidartinib), a CSF1R, KIT, and FLT3 inhibitor that was cleared for TGCT by the FDA in 2019, and potentially Ono's ...

A phase III trial showed a higher objective response rate with Romvimza than a separate phase III trial showed with Daiichi Sankyo Co. Ltd.’s Turalio (pexidartinib), and the latter’s label contains a ...

Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza (vimseltinib) to treat tenosynovial giant cell tumour (TGCT), introducing ...

TURALIO (pexidartinib, previously known as PLX3397) is a targeted therapy developed by Daiichi Sankyo for adult patients with symptomatic tenosynovial giant cell tumor that leads to significant ...